Table 3.
Clinical characteristics based on radiological findings in patients with COVID-19 (N = 249).
| Clinical characteristics | X-Ray findings, Mean ± SD |
p-value | |
|---|---|---|---|
| Normal (n = 191) | Abnormal (n = 58) | ||
| White blood cell count, × 109/L | 7.48 ± 3.30 | 7.96 ± 5.65 | 0.002* |
| Neutrophils count, × 109/L | 62.49 ± 13.91 | 80.19 ± 13.74 | <0.001 |
| Lymphocytes count, × 109/L | 29.89 ± 12.73 | 16.06 ± 17.43 | <0.001 |
| Platelet, × 109/L | 200.66 ± 90.81 | 175.71 ± 92.98 | 0.038 |
| Hb, g/L | 12.58 ± 2.43 | 12.09 ± 2.14 | 0.113 |
| PT, s | 13.51 ± 5.42 | 16.08 ± 7.53 | 0.002* |
| aPTT, s | 32.57 ± 14.70 | 39.44 ± 10.49 | 0.032 |
| Serum sodium, mmol/L | 138.13 ± 4.40 | 139.10 ± 7.20 | 0.184 |
| Serum potassium, mmol/L | 4.12 ± 0.55 | 4.46 ± 0.93 | <0.001 |
| Serum chloride, mmol/L | 96.17 ± 11.51 | 95.11 ± 8.12 | 0.437 |
| AST, U/L | 43.05 ± 45.43 | 86.12 ± 112.77 | <0.001 |
| ALT, U/L | 42.41 ± 45.25 | 100.41 ± 215.81 | <0.001 |
| LDH, U/L | 681.58 ± 684.23 | 827.62 ± 471.90 | 0.461 |
| Direct bilirubin, mmol/L | 0.69 ± 2.49 | 0.57 ± 1.19 | 0.629 |
| Indirect bilirubin, mmol/L | 0.54 ± 1.70 | 0.55 ± 1.38 | 0.957 |
| TBIL, mmol/L | 1.23 ± 4.15 | 1.12 ± 2.54 | 0.829 |
| CRP, mg/L | 20.88 ± 46.17 | 118.96 ± 11.43 | <0.001 |
| D-dimer, ng/mL | 713.63 ± 774.60 | 741.30 ± 572.83 | 0.890 |
| CPK-MB | 33.06 ± 22.26 | 49.64 ± 59.02 | 0.065 |
| Procal, ng/mL | 0.55 ± 1.54 | 16.73 ± 21.38 | <0.001 |
| PaO2, mmHg | 93.20 ± 8.60 | 79.94 ± 18.69 | <0.001 |
| SpO2, % | 96.92 ± 3.96 | 90.19 ± 7.93 | <0.001 |
LDL low-density lipoprotein; HDL high-density lipoprotein; TBIL total bilirubin; ALT alanine aminotransferase; AST aspartate transaminase; CK-MB creatinine kinase muscle and brain; APTT activated partial thromboplastin time; PT prothrombin time; CRP C –reactive protein; Proca procalcitonin; Hb hemoglobin; P < 0.05 was considered significant.